AI Article Synopsis

  • - Uterine adenosarcoma is a rare, biphasic tumor that includes both benign and malignant components, with prognosis influenced by factors like myometrial invasion and the presence of a sarcomatous overgrowth.
  • - Stage I adenosarcomas without sarcomatous overgrowth have a favorable 5-year survival rate of up to 80%, and surgical removal is the recommended treatment for localized cases.
  • - For advanced or metastatic cases, treatment options vary: low-grade tumors may respond to hormone therapy, while high-grade tumors typically require doxorubicin-based chemotherapy, often combined with surgical approaches.

Article Abstract

Uterine adenosarcoma is a very rare malignancy defined as a biphasic tumor composed of both benign epithelial component and a malignant sarcoma component. The stage of the disease is determined by the presence of myometrial invasion and the extent of extra-uterine disease. The most important histopronostic factors are the existence of a sarcomatous overgrowth defined by a sarcomatous contingent occupying more than 25 % of the volume of the tumor (directly correlated to the grade of the disease), the presence of a heterologous and/or a high-grade component. Stage I adenosarcomas without sarcomatous overgrowth have a good prognosis, with an overall 5-year survival of up to 80 %. In localized disease, complete surgical removal is recommended. The role of hormone therapy, chemotherapy and adjuvant radiotherapy is not established. If possible, relapses should be re-treated surgically, with the aim of achieving complete resection. In the advanced inoperable or metastatic setting, hormone therapy is an option for low-grade adenosarcomas with estrogen receptor (ER) and progesterone receptor (PR) overexpression. For high-grade tumors, the standard chemotherapies are doxorubicin-based combinations, although an integrated approach of surgery and medical treatment should also be considered in this setting.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2023.04.017DOI Listing

Publication Analysis

Top Keywords

component stage
8
sarcomatous overgrowth
8
hormone therapy
8
[uterin adenosarcoma
4
adenosarcoma french
4
french guidelines
4
guidelines french
4
french sarcoma
4
sarcoma group
4
group rare
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!